Rivercell
AI virtual-cell models predicting drug and genetic responses
About Rivercell
Rivercell is developing a programmable platform designed to create a comprehensive model of human cells, enabling the prediction of cellular responses to various treatments. This platform utilizes advanced methodologies such as live-cell imaging, longitudinal tracking of cellular responses, and multimodal data integration across diverse cell types and environments to enhance experimental outcomes and treatment predictions.
Rivercell is a company founded in 2025, now around 10 people. It has raised $25M in disclosed funding. FundFinder classes it as AI & ML.
Founded by Yann Fleureau (Co-Founder & CEO; repeat founder; previously Cardiologs, Project Numina; University of California, Berkeley), Eric Durand (Co-founder and Chief Science Officer; repeat founder; previously 23andMe, Bioptimus; Grenoble INP - UGA).
Its investors also appear on FundFinder's most-active lists for Seed · Fintech (111 funds), Seed · Generalist (110 funds), Seed · SaaS (37 funds).
Company facts from Harmonic and public filings; team backgrounds from public profiles. Refreshed weekly.
Seed · $25M · Oct 2026
- Alven — One of France's longest-standing independent early-stage firms, investing from a ~€350m sixth fund at seed and Series A. · cheques £1M – £10M
- HV Capital — Formerly HV Holtzbrinck Ventures — one of Europe's largest early-stage and growth investors, managing around €3B across nine fund generations and backing companies from seed through growth with cheques from ~€500k to €50 · cheques £400k – £40M